Reverse Sequential Therapy Achieves a Similar Eradication Rate as Standard Sequential Therapy forHelicobacter pyloriEradication: A Randomized Controlled Trial

Helicobacter ◽  
2014 ◽  
Vol 20 (1) ◽  
pp. 71-77 ◽  
Author(s):  
Feng-Woei Tsay ◽  
Deng-Chyang Wu ◽  
Sung-Shuo Kao ◽  
Tzung-Jium Tsai ◽  
Kwok-Hung Lai ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Eradication Rate ◽  
Controlled Trial ◽  
Sequential Therapy ◽  
Randomized Controlled

scholarly journals Randomized Controlled Trial for Helicobacter pylori Eradication in a Naive Portuguese Population: Is Sequential Treatment Superior to Triple Therapy in Real World Clinical Setting?

2017 ◽  
Vol 30 (3) ◽  
pp. 185 ◽  
Author(s):  
Pedro Boal Carvalho ◽  
Joana Magalhães ◽  
Francisca Dias de Castro ◽  
Bruno Rosa ◽  
José Cotter
Keyword(s):  
Randomized Controlled Trial ◽  
Helicobacter Pylori ◽  
Triple Therapy ◽  
Eradication Rate ◽  
Controlled Trial ◽  
Sequential Therapy ◽  
First Line ◽  
Portuguese Population ◽  
Helicobacter Pylori Eradication ◽  
Randomized Controlled

Introduction: Helicobacter pylori eradication has become increasingly difficult as resistances to several antibiotics develop. We aimed to compare Helicobacter pylori eradication rates between triple therapy and sequential therapy in a naive Portuguese population.Material and Methods: Prospective randomized trial including consecutive patients referred for first-line Helicobacter pylori eradication treatment. Exclusion criteria: previous gastric surgery/neoplasia, pregnancy/lactancy, allergy to any of the drugs. The compared eradication regimens were triple therapy (pantoprazol, amoxicillin and clarithromycin 12/12 hours, 14 days) and sequential therapy (pantoprazol 12/12 hours for 10 days, amoxicillin 12/12 hours for days 1 - 5 and clarithromycin plus metronidazol 12/12 hours during days 6 - 10). Eradication success was confirmed with urea breath test. Statistical analysis was performed with SPSS v21.0 and a p-value < 0.05 was considered statistically significant.Results: Included 60 patients, 39 (65%) female with mean age 52 years (SD ± 14.3). Treatment groups were homogeneous for gender, age, indication for treatment and smoking status. No statistical differences were encountered between sequential and triple therapy eradication rates (86.2% vs 77.4%, p = 0.379), global eradication rate was 82%. Tobacco consumption was associated with a significantly lower eradication success (54.5 vs 87.8%, p = 0.022).Discussion: In this randomized controlled trial in a naive Portuguese population, we found a satisfactory global Helicobacter pylori eradication rate of 82%, with no statistical differences observed in the efficacy of the treatment between triple and sequential regimens.Conclusion: These results support the use of either therapy for the first-line eradication of Helicobacter pylori.

scholarly journals Vonoprazan-Based Regimen Is More Useful than PPI-Based One as a First-LineHelicobacter pyloriEradication: A Randomized Controlled Trial

2017 ◽  
Vol 2017 ◽  
pp. 1-7 ◽  
Author(s):  
Masafumi Maruyama ◽  
Naoki Tanaka ◽  
Daisuke Kubota ◽  
Masayuki Miyajima ◽  
Takefumi Kimura ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Adverse Events ◽  
Eradication Rate ◽  
Controlled Trial ◽  
Eradication Therapy ◽  
Group Versus ◽  
Intention To Treat ◽  
Randomized Controlled ◽  
Primary Endpoints ◽  
H Pylori

Background. A new agent, potassium-competitive acid blocker vonoprazan (VPZ) has potent acid-inhibitory effects and may offer advantages over conventionalH. pylorieradication therapies. We aimed to compare the eradication rate between VPZ-based treatment and PPI-based one.Methods. This randomized controlled trial was designed to assign 141 patients withH. pylori-positive gastritis to VPZ group (VPZ 20 mg, amoxicillin 750 mg, and clarithromycin 200 or 400 mg twice daily for 7 days) or PPI group (rabeprazole 20 mg or lansoprazole 30 mg, amoxicillin 750 mg, and clarithromycin 200 or 400 mg twice daily for 7 days). Primary endpoints were eradication rates and adverse events.Results. Seventy of 72 patients in VPZ group and 63 of 69 patients in PPI group completed the treatment after 7 days. The eradication rate was significantly higher in VPZ group than PPI group by intention-to-treat analysis (95.8% versus 69.6%,P=0.00003, 95% confidence interval [CI] 88.3-99.1% versus 57.3-80.1%) and per-protocol analysis (95.7% versus 71.4%,P=0.0002, 95% CI 88.0-99.1% versus 58.7-82.1%). The incidence of adverse events was not different between the groups (26.3% in VPZ group versus 37.7% in PPI group,P=0.15).Conclusion. VPZ-based regimen is more useful than that PPI-based regimen as a first-lineH. pylorieradication therapy.

scholarly journals A Multi-Institutional Randomized Controlled Trial to Investigate Whether Zoledronate Prevents Bone Loss After Discontinuation of Denosumab: The Study Protocol of Denosumab Sequential Therapy (DST) Trial

2021 ◽  
Vol 8 ◽  
Author(s):  
Chia-Che Lee ◽  
Chen-Yu Wang ◽  
Chih-Chien Hung ◽  
Chuan-Ching Huang ◽  
Chung-Yi Li ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Bone Loss ◽  
Controlled Trial ◽  
Rebound Effect ◽  
Sequential Therapy ◽  
Drug Holiday ◽  
Controlled Study ◽  
Mineral Density ◽  
Randomized Controlled ◽  
Increased Risk

Background: Though denosumab is an effective treatment for osteoporosis, the rebound effect after discontinuation has drawn investigators' attention. It includes a dramatic loss of gained bone mineral density (BMD) and an increased risk of vertebral fractures. This prospective multi-institutional randomized controlled trial aims to investigate whether zoledronate prevents loss of BMD after discontinuation of denosumab. The trial was registered as Denosumab Sequential Therapy (DST) trial in March 2019 at clinicaltrials.gov, with the identifier NCT03868033.Methods: The study is conducted at National Taiwan University Hospital and its branches. Patients who have continuously received denosumab treatment for two or more years are surveyed for eligibility. Baseline characteristics and questionnaires of life quality are recorded after recruitment. BMD, circulating levels of bone turnover markers (BTMs), including serum N-terminal propeptide of type 1 collagen (P1NP) and C-terminal telopeptide (CTX), are checked before the stratified randomization to 4 groups. Biological sex and the T-scores are used to create 4 strata. The participants in group 1 adhere to regular denosumab therapy for another 2 years. All the other patients receive on-time zoledronate treatment in the first year. The participants in group 2, 3, and 4 have on-time denosumab, on-time zoledronate and drug holiday in the second year, respectively. BMDs are checked annually. Pre-scheduled checkpoints of BTMs are also arranged. For patient safety, rescue treatment with another injection of zoledronate will be applied to the patients on drug holiday if the CTX levels raise above the pre-specified threshold, 0.573 ng/mL for women and 0.584 ng/mL for men. The primary outcomes are the percentage changes of BMDs in lumbar spine, total hip and femoral neck. The secondary outcomes include the changes of serum level of the BTMs, new osteoporotic fractures, extra zoledronate injections needed in group 4 and the differences of quality of life.Discussion: We aim to provide evidence whether zoledronate prevents bone loss after denosumab cessation. To our knowledge, the study has the largest sample size. No other randomized controlled study included all the three different treatment strategies and a positive control. It is also the first associated randomized controlled trial outside Europe.

scholarly journals Hybrid therapy versus sequential therapy for eradication of Helicobacter pylori: A randomized controlled trial

2017 ◽  
Vol 8 (2) ◽  
pp. 62 ◽  
Author(s):  
Vikram Kate ◽  
Sahoo Ashokkumar ◽  
Sonia Agrawal ◽  
Jharna Mandal ◽  
Sathasivam Sureshkumar ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Helicobacter Pylori ◽  
Controlled Trial ◽  
Sequential Therapy ◽  
Hybrid Therapy ◽  
Randomized Controlled

Tu2083 A Randomized Controlled Trial Comparing the First-Line Eradication Rate Using Vonoprazan or PPI for Helicobacter pylori Infectious Gastritis

2016 ◽  
Vol 150 (4) ◽  
pp. S1269 ◽  
Author(s):  
Masafumi Maruyama ◽  
Daisuke Kubota ◽  
Masayuki Miyajima ◽  
Takefumi Kimura ◽  
Koujiro Tokutake ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Helicobacter Pylori ◽  
Eradication Rate ◽  
Controlled Trial ◽  
First Line ◽  
Randomized Controlled
Sign in / Sign up

Export Citation Format

Share Document